- Home
- AKBA vs NKX Comparison
AKBA vs NKX Comparison
Compare AKBA & NKX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- NKX
- Stock Information
- Founded
- AKBA 2007
- NKX 2002
- Country
- AKBA United States
- NKX United States
- Employees
- AKBA N/A
- NKX N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- NKX Finance/Investors Services
- Sector
- AKBA Health Care
- NKX Finance
- Exchange
- AKBA Nasdaq
- NKX Nasdaq
- Market Cap
- AKBA 729.1M
- NKX 613.8M
- IPO Year
- AKBA 2014
- NKX N/A
- Fundamental
- Price
- AKBA $1.68
- NKX $12.86
- Analyst Decision
- AKBA Strong Buy
- NKX
- Analyst Count
- AKBA 6
- NKX 0
- Target Price
- AKBA $6.25
- NKX N/A
- AVG Volume (30 Days)
- AKBA 5.5M
- NKX 109.3K
- Earning Date
- AKBA 11-10-2025
- NKX 01-01-0001
- Dividend Yield
- AKBA N/A
- NKX 4.37%
- EPS Growth
- AKBA N/A
- NKX N/A
- EPS
- AKBA N/A
- NKX N/A
- Revenue
- AKBA $225,071,000.00
- NKX N/A
- Revenue This Year
- AKBA $53.38
- NKX N/A
- Revenue Next Year
- AKBA $30.53
- NKX N/A
- P/E Ratio
- AKBA N/A
- NKX N/A
- Revenue Growth
- AKBA 32.49
- NKX N/A
- 52 Week Low
- AKBA $1.52
- NKX $9.78
- 52 Week High
- AKBA $4.08
- NKX $12.00
- Technical
- Relative Strength Index (RSI)
- AKBA 24.68
- NKX 65.45
- Support Level
- AKBA $2.07
- NKX $12.82
- Resistance Level
- AKBA $3.19
- NKX $12.98
- Average True Range (ATR)
- AKBA 0.16
- NKX 0.07
- MACD
- AKBA -0.09
- NKX 0.00
- Stochastic Oscillator
- AKBA 6.19
- NKX 76.83
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About NKX Nuveen California AMT-Free Quality Municipal Income Fund
Nuveen California AMT-Free Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objectives are to provide current income exempt from regular federal and California income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.